# Phase 1/2 Lymphoma, Large B-Cell, Diffuse trials: 41 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 41 trials in phase 1/2 for Lymphoma, Large B-Cell, Diffuse that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Lymphoma, Large B-Cell, Diffuse trials: 41 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/lymphoma-large-b-cell-diffuse

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 41
- Recruiting or not yet: 41
- Read on: November 19, 2026

## Trials

The 25 newest of 41, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07932730 | Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell... | University of Michigan Rogel Cancer Center | Phase 1/2 | Not yet recruiting | Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932730) |
| October 21, 2026 | NCT07887750 | REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887750) |
| September 14, 2026 | NCT07818499 | A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818499) |
| August 26, 2026 | NCT07788118 | A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 1/2 | Recruiting | Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788118) |
| August 6, 2026 | NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | Vitruviae | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome, Solid Tumor... | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749976) |
| July 30, 2026 | NCT07735533 | A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies | Umoja Biopharma | Phase 1/2 | Recruiting | Lymphoma, B Cell, Lymphoma Non-Hodgkin, High Grade B Cell Lymphoma, Richter Transformation Lymphoma, Grade 3b... | 274 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735533) |
| May 27, 2026 | NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1/2 | Recruiting | Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström... | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609862) |
| May 22, 2026 | NCT07601607 | Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma | Sun Yat-sen University | Phase 1/2 | Not yet recruiting | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601607) |
| April 9, 2026 | NCT07519772 | A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519772) |
| March 16, 2026 | NCT07473167 | Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients | TICAROS Co., Ltd. | Phase 1/2 | Recruiting | Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High-grade... | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473167) |
| February 10, 2026 | NCT07398638 | Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study | Sun Yat-sen University | Phase 1/2 | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL) | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07398638) |
| December 16, 2025 | NCT07284433 | Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies | AvenCell Therapeutics, Inc. | Phase 1/2 | Recruiting | Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284433) |
| September 8, 2025 | NCT07159906 | Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | First Affiliated Hospital of Zhejiang University | Phase 1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07159906) |
| August 15, 2025 | NCT07124936 | A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Diffuse Large B Cell Lymphoma (DLBCL) | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07124936) |
| July 11, 2025 | NCT07059650 | DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) | Dizal Pharmaceuticals | Phase 1/2 | Recruiting | Diffuse Large B-Cell Lymphoma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07059650) |
| June 25, 2025 | NCT07035379 | A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With... | Zhejiang Teruisi Pharmaceutical Inc. | Phase 1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07035379) |
| March 30, 2025 | NCT06902012 | Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma | Zhujiang Hospital | Phase 1/2 | Recruiting | Relapsed/Refractory Diffuse Large B-cell Lymphoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06902012) |
| February 17, 2025 | NCT06829771 | Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1/2 | Recruiting | Diffuse Large B Cell Lymphoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06829771) |
| January 10, 2025 | NCT06768905 | IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL | University of Texas Southwestern Medical Center | Phase 1/2 | Recruiting | Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06768905) |
| January 6, 2025 | NCT06760039 | Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL | Sun Yat-sen University | Phase 1/2 | Recruiting | Diffuse Large B-Cell Lymphoma | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06760039) |
| September 19, 2024 | NCT06594640 | R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | Recruiting | Diffuse Large B-cell Lymphoma | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06594640) |
| August 2, 2024 | NCT06536049 | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma... | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06536049) |
| August 1, 2024 | NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | Vironexis Biotherapeutics Inc. | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06533579) |
| May 1, 2024 | NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors... | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06395103) |
| April 19, 2024 | NCT06375733 | A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL | Genfleet Therapeutics (Shanghai) Inc. | Phase 1/2 | Recruiting | Large B-cell Lymphoma | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06375733) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sun Yat-sen University | 3 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 2 |
| Genfleet Therapeutics (Shanghai) Inc. | 1 |
| Jonsson Comprehensive Cancer Center | 1 |
| OHSU Knight Cancer Institute | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| Lyell Immunopharma, Inc. | 1 |
| Vironexis Biotherapeutics Inc. | 1 |
| Essen Biotech | 1 |
| New York Medical College | 1 |
| Curocell Inc. | 1 |
| University Hospital Heidelberg | 1 |
| TICAROS Co., Ltd. | 1 |
| Kartos Therapeutics, Inc. | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |
| National Cancer Institute (NCI) | 1 |
| [Dizal Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/dizal-pharmaceuticals) | 1 |
| [Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd) | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 1 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 1 |
| AVM Biotechnology Inc | 1 |
| AvenCell Therapeutics, Inc. | 1 |
| National Health Research Institutes, Taiwan | 1 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | 1 |
| University of Michigan Rogel Cancer Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 18 |
| China | 17 |
| South Korea | 7 |
| United Kingdom | 6 |
| Australia | 5 |
| France | 5 |
| Germany | 5 |
| Italy | 5 |
| Spain | 5 |
| Brazil | 3 |
| Canada | 3 |
| Turkey (Türkiye) | 3 |
| Poland | 3 |
| Belgium | 2 |
| Chile | 2 |
| Czechia | 2 |
| Israel | 2 |
| Sweden | 2 |
| Colombia | 1 |
| Denmark | 1 |
| Greece | 1 |
| Hungary | 1 |
| Netherlands | 1 |
| Slovakia | 1 |
| Taiwan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Electronic parts suppliers in the United States](https://specstream.ai/data/businesses/electronic-parts-suppliers/united-states)
- [Interior design firms in the United States](https://specstream.ai/data/businesses/interior-design-firms/united-states)
- [Pediatric oncology practices in the United States](https://specstream.ai/data/businesses/pediatric-oncology-practices/united-states)
- [Taiwanese restaurants in the United States](https://specstream.ai/data/businesses/taiwanese-restaurants/united-states)
- [B2B domestic trade companies in the United States](https://specstream.ai/data/businesses/b2b-domestic-trade-companies/united-states)
- [Credit unions in the United States](https://specstream.ai/data/businesses/credit-unions/united-states)
